Switch theme
Sign up to access all valuation multiples
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
2011
2.0K+
LTM Revenue $773M
LTM EBITDA -$248M
$6.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Guardant Health has a last 12-month revenue of $773M and a last 12-month EBITDA of -$248M.
In the most recent fiscal year, Guardant Health achieved revenue of $739M and an EBITDA of -$390M.
Guardant Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Guardant Health valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $564M | $739M | XXX | XXX | XXX |
| Gross Profit | $293M | $337M | XXX | XXX | XXX |
| Gross Margin | 52% | 46% | XXX | XXX | XXX |
| EBITDA | -$433M | -$390M | XXX | XXX | XXX |
| EBITDA Margin | -77% | -53% | XXX | XXX | XXX |
| Net Profit | -$655M | -$479M | XXX | XXX | XXX |
| Net Margin | -116% | -65% | XXX | XXX | XXX |
| Net Debt | $996M | $6.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Guardant Health's stock price is $45.
Guardant Health has current market cap of $5.6B, and EV of $6.1B.
See Guardant Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.1B | $5.6B | XXX | XXX | XXX | XXX | $-3.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Guardant Health has market cap of $5.6B and EV of $6.1B.
Guardant Health's trades at 7.9x LTM EV/Revenue multiple, and -24.5x LTM EBITDA.
Analysts estimate Guardant Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Guardant Health and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.1B | XXX | XXX | XXX |
| EV/Revenue | 8.2x | XXX | XXX | XXX |
| EV/EBITDA | -15.6x | XXX | XXX | XXX |
| P/E | -12.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -22.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGuardant Health's NTM/LTM revenue growth is 18%
Guardant Health's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Guardant Health's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Guardant Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Guardant Health and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -53% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -35% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 49% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 24% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 47% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 121% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guardant Health acquired XXX companies to date.
Last acquisition by Guardant Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Guardant Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Guardant Health founded? | Guardant Health was founded in 2011. |
| Where is Guardant Health headquartered? | Guardant Health is headquartered in United States of America. |
| How many employees does Guardant Health have? | As of today, Guardant Health has 2.0K+ employees. |
| Who is the CEO of Guardant Health? | Guardant Health's CEO is Mr. Helmy Eltoukhy. |
| Is Guardant Health publicy listed? | Yes, Guardant Health is a public company listed on NAS. |
| What is the stock symbol of Guardant Health? | Guardant Health trades under GH ticker. |
| When did Guardant Health go public? | Guardant Health went public in 2018. |
| Who are competitors of Guardant Health? | Similar companies to Guardant Health include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Guardant Health? | Guardant Health's current market cap is $5.6B |
| What is the current revenue of Guardant Health? | Guardant Health's last 12-month revenue is $773M. |
| What is the current EBITDA of Guardant Health? | Guardant Health's last 12-month EBITDA is -$248M. |
| What is the current EV/Revenue multiple of Guardant Health? | Current revenue multiple of Guardant Health is 7.9x. |
| What is the current EV/EBITDA multiple of Guardant Health? | Current EBITDA multiple of Guardant Health is -24.5x. |
| What is the current revenue growth of Guardant Health? | Guardant Health revenue growth between 2023 and 2024 was 31%. |
| Is Guardant Health profitable? | Yes, Guardant Health is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
